A Phase 1 Study of Safety and Bioactivity With FG-3019 in Combination With Gemcitabine and Erlotinib for Subjects With Locally Advanced or Metastatic Pancreatic Cancer
Objectives

* Primary: To evaluate the safety and tolerability of FG-3019 in combination with gemcitabine and erlotinib
* Secondary: To evaluate the efficacy and pharmacokinetics of FG-3019 in combination with gemcitabine and erlotinib
Locally Advanced or Metastatic Pancreatic Cancer
DRUG: FG-3019
To evaluate the safety and tolerability of FG-3019 in combination with gemcitabine and erlotinib, Through the end of the study
FG-3019 PK parameters, Through the end of the study|Time to Progression (TTP), Through the end of the study|6-month, 12-month and overall median survival rates, Through the end of the study|Maximal tumor response as determined by RECIST criteria, Through the end of the study
Objectives

* Primary: To evaluate the safety and tolerability of FG-3019 in combination with gemcitabine and erlotinib
* Secondary: To evaluate the efficacy and pharmacokinetics of FG-3019 in combination with gemcitabine and erlotinib